Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Shi

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
European Journal of Heart Failure|August 21, 2014
Impaired left atrial function in heart failure with preserved ejection fractionAngela B S Santos, Elisabeth Kraigher-Krainer, Deepak K Gupta, et al.
European Heart Journal|May 30, 2015
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patientsAkshay S Desai, John J V McMurray, Milton Packer, et al.
European Journal of Heart Failure|January 6, 2022
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failureFinnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
Circulation|August 27, 2020
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection FractionFinnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
Circulation. Heart Failure|March 12, 2021
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF AnalysisLuis E Rohde, Brian L Claggett, Emil Wolsk, et al.
JACC. Heart Failure|July 11, 2021
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF TrialMauro Gori, Michele Senni, Brian Claggett, et al.
Circulation|November 19, 2019
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart FailureScott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
European Journal of Heart Failure|December 12, 2018
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the AmericasPooja Dewan, Pardeep S Jhund, Li Shen, et al.
European Heart Journal|November 23, 2014
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failureJohn McMurray, Milton Packer, Akshay Desai, et al.
Circulation. Heart Failure|March 31, 2017
Reassessing Phase II Heart Failure Clinical Trials: Consensus RecommendationsJaved Butler, Carine E Hamo, James E Udelson, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
European Journal of Heart Failure|August 21, 2014
Impaired left atrial function in heart failure with preserved ejection fractionAngela B S Santos, Elisabeth Kraigher-Krainer, Deepak K Gupta, et al.
European Heart Journal|May 30, 2015
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patientsAkshay S Desai, John J V McMurray, Milton Packer, et al.
European Journal of Heart Failure|January 6, 2022
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failureFinnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
Circulation|August 27, 2020
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection FractionFinnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
Circulation. Heart Failure|March 12, 2021
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF AnalysisLuis E Rohde, Brian L Claggett, Emil Wolsk, et al.
JACC. Heart Failure|July 11, 2021
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF TrialMauro Gori, Michele Senni, Brian Claggett, et al.
Circulation|November 19, 2019
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart FailureScott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
European Journal of Heart Failure|December 12, 2018
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the AmericasPooja Dewan, Pardeep S Jhund, Li Shen, et al.
European Heart Journal|November 23, 2014
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failureJohn McMurray, Milton Packer, Akshay Desai, et al.
Circulation. Heart Failure|March 31, 2017
Reassessing Phase II Heart Failure Clinical Trials: Consensus RecommendationsJaved Butler, Carine E Hamo, James E Udelson, et al.
Pageof 7